Democritus University of Thrace (DUTH)
Ανάπτυξη και αξιολόγηση συστήματος ανθρωποποιημένων ποντικών ως προκλινικό μοντέλο καινοτόμων αντικαρκινικών ανοσοθεραπειών
Abstract
dc:descriptionCancer immunotherapy engages a patient’s own immune system in the fight against tumors. Checkpoint blockade inhibitors, cancer vaccines and other immunotherapeutic modalities have shown promising results in multiple malignancies. However, a significant percentage of patients still do not benefit from immunotherapy due to a number of reasons. On one hand, variability in patient responses due to HLA polymorphism, individuality of antigens (i.e. cancer neo-antigens) and uniqueness of the tumor microenvironment’s immunosuppressive nature per se highlight the need for more personalized approaches in antigenic epitope discovery. In this direction, mass spectrometry (MS)- based immunopeptidomics have facilitated the direct identification of potential therapeutic candidates. On the other hand, current pre-clinical models often prove to be inadequate as immunotherapeutic tools, since they only partially recapitulate the clinical reality of human cancers. Therefore, mice with human components, including patient-derived tumors and / or a complete human immune system provide a more suitable setting for the development and testing of new immunotherapies. In this thesis, we developed various humanized mouse models, namely, patient derived xenograft (PDX) mice from various tumor types, as well as human immune system (HIS) and bone- liver-thymus (BLT) mice that have developed a functional human immune system. We then explored their potential as pre-clinical models for tumor immunotherapy. In one study, we established an epithelial ovarian cancer PDX model, in which we assessed the efficacy of T cell responses elicited in patients vaccinated with an autologous dendritic cell-based vaccine. In a second set of experiments, we developed and optimized a HIS mouse model for application in checkpoint blockade inhibition studies, where engrafted non-small cell lung cancer tumors were treated with blocking human anti-PD-1 monoclonal antibodies. Last but not least, we introduced the use of a humanized mouse model for antigen discovery and immunogenicity validation. As a proof of concept, BLT mice were vaccinated with an H5N1 influenza virus, which elicited strong virus-specific immune responses. Mass-spectrometry-based immunopeptidomic analysis identified multiple virus-derived human leukocyte antigen (HLA) class I and II ligands presented by the in vivo generated human antigen presenting cells (APCs) loaded with virus. Their immunogenicity was validated in ex vivo experiments that revealed predominantly CD4+ T cell responses against multiple ligands. Thus, for the first time we describe the application of immunopeptidomics on a humanized mouse model as a novel strategy for the discovery of patient specific, clinically-relevant targets. In summary, using different approaches we provided evidence that humanized mice constitute superior models for epitope discovery and immunotherapeutic studies in a human context in vivo.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Semilietof, Aikaterini
- Σεμιλιέτωφ, Αικατερίνη
Subjects
dc:subject × 6Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46049